Related Experiment Video
Updated: Jan 27, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?
Igor Tsaur1, Isabel Heidegger2, Alexander Kretschmer3
1Department of Urology and Pediatric Urology, Mainz University Medicine, Mainz, Germany.
Abstract:
Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has led to a striking improvement of response rate and survival in both hormone-sensitive and castration-resistant disease. In most cases, prostate cancer essentially depends on androgen receptor signaling axis, even in castration-resistant setting, and hence may be targeted by second generation hormonal therapy. However, a subset of patients bears androgen-independent cancer biology with a short-term response to hormonal treatment, early and extensive visceral metastases, low PSA levels and poor outcomes. Identification and specific management of these rapidly fatal malignancies is of an unmet medical need since their classification and utilized therapeutic regimens vary significantly. Unfortunately, molecular pathways have not been sufficiently elucidated yet in order to provide an effective targeted treatment with a prolonged response. Lack of diagnostic and predictive biomarkers for these cancers makes successful counteractions against them even more sophisticated. In this comprehensive review, we aimed at summarizing the current body of literature reporting on causal molecular machinery as well as diagnostic and therapeutic concepts of aggressive prostate tumors and draw clinically relevant conclusions for the up-to-date sensible disease management.
Insights
Aggressive prostate cancer, independent of androgen receptor signaling, presents unique challenges. This review summarizes molecular insights and management strategies for these rapidly fatal tumors.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Metastatic prostate cancer treatment has improved, yet a subset exhibits androgen-independent biology.
- These aggressive tumors feature early visceral metastases, low PSA, and poor outcomes, posing a significant unmet medical need.
- Current understanding of molecular pathways and biomarkers for these aggressive prostate cancers is limited.
Purpose of the Study:
- To review the current literature on the molecular mechanisms driving aggressive prostate tumors.
- To summarize diagnostic and therapeutic strategies for these challenging malignancies.
- To provide clinically relevant conclusions for improved disease management.
Main Methods:
- Comprehensive literature review of studies on aggressive prostate cancer.
- Analysis of molecular pathways, diagnostic biomarkers, and therapeutic regimens.
- Synthesis of findings to inform clinical practice.
Main Results:
- Prostate cancer often relies on androgen receptor signaling, but aggressive forms can be androgen-independent.
- These aggressive cancers are characterized by distinct clinical features and poor response to standard therapies.
- Limited knowledge of underlying molecular machinery hinders effective targeted treatment development.
Conclusions:
- Effective management of aggressive prostate cancer requires understanding its unique molecular drivers.
- Development of specific diagnostic and predictive biomarkers is crucial.
- Further research into targeted therapies is essential for improving outcomes in these patients.
Related Concept Videos
Aggression
Treatment Resistant Cancers
Ready Mixed Concrete
Histone Variants at the Centromere
Secondary Motives: Affiliation Motivation and Aggression Motivation
Substitution Rule Applied to Indefinite Integrals

